The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarkers for immunotherapy: Results from the analysis of an HLA-status double-blind, biologically randomized phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as first-line therapy for advanced colorectal cancer (FXV study).
Shoichi Hazama
No relevant relationships to disclose
Yusuke Nakamura
Consultant or Advisory Role - OncoTherapy Science (U)
Stock Ownership - OncoTherapy Science
Hiroaki Tanaka
No relevant relationships to disclose
Ko Tahara
No relevant relationships to disclose
Ryoichi Shimizu
No relevant relationships to disclose
Fumiaki Sugiura
No relevant relationships to disclose
Kiyotaka Okuno
No relevant relationships to disclose
Koichiro Sakata
No relevant relationships to disclose
Kazuhiko Yoshimatsu
No relevant relationships to disclose
Hiroko Takenouchi
No relevant relationships to disclose
Ryouichi Tsunedomi
No relevant relationships to disclose
Yuka Inoue
No relevant relationships to disclose
Shinsuke Kanekiyo
No relevant relationships to disclose
Yoshitaro Shindo
No relevant relationships to disclose
Shigefumi Yoshino
No relevant relationships to disclose
Hirokazu Shinozaki
No relevant relationships to disclose
Hiroyuki Furukawa
No relevant relationships to disclose
Tomonobu Fujita
No relevant relationships to disclose
Yutaka Kawakami
No relevant relationships to disclose
Masaaki Oka
No relevant relationships to disclose